1. Home
  2. MIRM vs ADUS Comparison

MIRM vs ADUS Comparison

Compare MIRM & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • ADUS
  • Stock Information
  • Founded
  • MIRM 2018
  • ADUS 1979
  • Country
  • MIRM United States
  • ADUS United States
  • Employees
  • MIRM N/A
  • ADUS N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • ADUS Medical/Nursing Services
  • Sector
  • MIRM Health Care
  • ADUS Health Care
  • Exchange
  • MIRM Nasdaq
  • ADUS Nasdaq
  • Market Cap
  • MIRM 1.9B
  • ADUS 2.0B
  • IPO Year
  • MIRM 2019
  • ADUS 2009
  • Fundamental
  • Price
  • MIRM $39.10
  • ADUS $101.25
  • Analyst Decision
  • MIRM Strong Buy
  • ADUS Buy
  • Analyst Count
  • MIRM 11
  • ADUS 11
  • Target Price
  • MIRM $58.55
  • ADUS $134.73
  • AVG Volume (30 Days)
  • MIRM 476.2K
  • ADUS 269.1K
  • Earning Date
  • MIRM 05-07-2025
  • ADUS 05-05-2025
  • Dividend Yield
  • MIRM N/A
  • ADUS N/A
  • EPS Growth
  • MIRM N/A
  • ADUS 10.44
  • EPS
  • MIRM N/A
  • ADUS 4.23
  • Revenue
  • MIRM $336,888,000.00
  • ADUS $1,154,599,000.00
  • Revenue This Year
  • MIRM $29.51
  • ADUS $24.63
  • Revenue Next Year
  • MIRM $20.27
  • ADUS $5.91
  • P/E Ratio
  • MIRM N/A
  • ADUS $23.94
  • Revenue Growth
  • MIRM 80.76
  • ADUS 9.06
  • 52 Week Low
  • MIRM $23.14
  • ADUS $87.88
  • 52 Week High
  • MIRM $54.23
  • ADUS $136.72
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 34.64
  • ADUS 54.25
  • Support Level
  • MIRM $37.83
  • ADUS $98.29
  • Resistance Level
  • MIRM $40.32
  • ADUS $103.10
  • Average True Range (ATR)
  • MIRM 2.47
  • ADUS 3.92
  • MACD
  • MIRM -0.33
  • ADUS 0.71
  • Stochastic Oscillator
  • MIRM 25.14
  • ADUS 77.55

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Share on Social Networks: